In-house Products
SK bioscience develops vaccines with its innovative technology and produces them under a strict quality control system.
the world’s first-developed quadrivalent cell culture-based influenza vaccine
SKYCellflu® Quadrivalent Prefilled Syringe
(cell culture-based influenza vaccine)
Cell culture-derived influenza vaccine with SK Bioscience’s technology
SKY Cellflu prefilled syringe
(Cell-Cultured Influenza Vaccine)
The WHO PQ certification obtained varicella vaccine
SKYVaricella®
(Live Attenuated Vaccine)
WHO PQ prequalified typhoid conjugate vaccine
SKY Typhoid Multi Inj.
(Thyphoid purified Vi Polysaccharide Conjugated to Diphtheria toxoid vaccine)
The first Korean-developed COVID-19 Vaccine
SKYCovione™
(SARS-CoV-2, Surface Antigen (Recombinant DNA))
